Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167036 | 1.00 | CYP2C9 (0.61) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL167037 | 1.00 | CYP2C9 (0.61) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL11652941 | 0.87 | CYP2C9 (0.47) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL11652946 | 0.87 | CYP2C9 (0.47) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL11106211 | 0.87 | CYP2C9 (0.56) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL31636860 | 0.85 | CYP2C9 (0.61) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL2671868 | 0.85 | CYP2C9 (0.43) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL2671866 | 0.85 | CYP2C9 (0.43) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL4546680 | 0.85 | CYP2C9 (0.61) | CYP2C9ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL4135128 | 0.85 | CYP2C9 (0.61) | CYP2C9ALDH1A1TSHRMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4655294-A1 | PYRAZOLE DERIVSTIVES AS PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | disclosed |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| WO-2025217420-A1 | PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-3727380-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-5849779-A | Pyrazole derivatives and their pharmaceutical use | JAPAN ENERGY CORPORATION (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0810217-A1 | Pyrazole derivatives and their pharmaceutical use as smooth muscle cell growth inhibitors | JAPAN ENERGY CORPORATION (JP) | 1997-12-03 | — | — | EP | disclosed |
| EP-0450073-B1 | 1-AZAINDOLIZINE DERIVATIVE, INTERMEDIATE FOR SYNTHESIS THEREOF, AND ANTIALLERGIC CONTAINING 1-AZAINDOLIZINE DERIVATIVE | ZENYAKU KOGYO KK (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-5112833-A | Dermatitis, rhinitis, asthma | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0450073-A1 | 1-AZAINDOLIZINE DERIVATIVE, INTERMEDIATE FOR SYNTHESIS THEREOF, AND ANTIALLERGIC CONTAINING 1-AZAINDOLIZINE DERIVATIVE | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-RE30024-E | ANTIALLERGENS | STERLING DRUG INC. (US) | 1979-06-05 | — | — | US | disclosed |
| US-4118571-A | ANTIALLERGENS | STERLING DRUG INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-4086233-A | ANTIALLERGENS | STERLING DRUG INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4032523-A | ANTIALLERGENS | STERLING DRUG INC. (US) | 1977-06-28 | — | — | US | disclosed |
| US-4018770-A | ANTIALLERGENS | STERLING DRUG INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | CYP2C9 1396/4885ALDH1A1 113/4885TSHR 4487/4885 |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | CYP2C9 2993/4885ALDH1A1 2069/4885TSHR 467/4885 |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | POT1, PARP15, TERT | CYP2C9 4754/4885ALDH1A1 2425/4885TSHR 3815/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | CYP2C9 2850/4885ALDH1A1 3515/4885TSHR 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.